Cargando…
Safety and adverse reactions in subcutaneous allergen immunotherapy: a review
BACKGROUND AND AIM: Allergen immunotherapy (AIT) is the only treatment which acts on the causes of allergic diseases by modifying their natural history. In the eighties subcutaneous immunotherapy (SCIT) with high bio-logical power allergen extracts caused a number of severe systemic reactions and al...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Mattioli 1885
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440773/ https://www.ncbi.nlm.nih.gov/pubmed/37539607 http://dx.doi.org/10.23750/abm.v94i4.14239 |
_version_ | 1785093224761655296 |
---|---|
author | Incorvaia, Cristoforo Cavaliere, Carlo Schroeder, Jan W. Leo, Gualtiero Nicoletta, Francesca Barone, Alessandro Ridolo, Erminia |
author_facet | Incorvaia, Cristoforo Cavaliere, Carlo Schroeder, Jan W. Leo, Gualtiero Nicoletta, Francesca Barone, Alessandro Ridolo, Erminia |
author_sort | Incorvaia, Cristoforo |
collection | PubMed |
description | BACKGROUND AND AIM: Allergen immunotherapy (AIT) is the only treatment which acts on the causes of allergic diseases by modifying their natural history. In the eighties subcutaneous immunotherapy (SCIT) with high bio-logical power allergen extracts caused a number of severe systemic reactions and also fatalities in the UK and the US, resulting in its limitation and in the introduction of other routes of administration. The aim of this review is to make a reflection about still unclear and unidentified factors favoring severe reactions during SCIT. METHODS: Approaches to prevent fatal or life-threatening reactions to AIT and the current consensus on how to prevent life-threatening reactions to AIT have been taken into account. RESULTS: A decisive advance for SCIT safety was understanding that the major cause of mortality was injecting the allergen extract to patients with uncontrolled asthma. This awareness resulted in a significant decrease in fatalities, but not in their abolition, except for Hymenoptera venom immunotherapy. Among the factors favoring severe reactions there are the administration of a wrong extract or of allergen doses higher than listed, unintentional intravenous administration, and missed dose reduction after protracted interruption. Moreover, in the context of the improving of the safety, the role played in tolerance-promoting by adjuvants such as CpG oligodeoxynucleotides has to be taken into account, as well as the potential preventive effect performed by the monoclonal anti-IgE antibody omalizumab against the exacerbation of severe reactions during SCIT. CONCLUSIONS: The safety of SCIT is good, but the research to improve it further must continue. In particular, the pathophysiological mechanisms related to AIT for inhalants and for Hymenoptera venom should be studied, based on the evident diversity demonstrated by the complete absence of fatal reactions to Hymenoptera venom immunotherapy from its introduction in comparison with the history of serious and fatal offenses examined in this review. (www.actabiomedica.it) |
format | Online Article Text |
id | pubmed-10440773 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Mattioli 1885 |
record_format | MEDLINE/PubMed |
spelling | pubmed-104407732023-08-22 Safety and adverse reactions in subcutaneous allergen immunotherapy: a review Incorvaia, Cristoforo Cavaliere, Carlo Schroeder, Jan W. Leo, Gualtiero Nicoletta, Francesca Barone, Alessandro Ridolo, Erminia Acta Biomed Review BACKGROUND AND AIM: Allergen immunotherapy (AIT) is the only treatment which acts on the causes of allergic diseases by modifying their natural history. In the eighties subcutaneous immunotherapy (SCIT) with high bio-logical power allergen extracts caused a number of severe systemic reactions and also fatalities in the UK and the US, resulting in its limitation and in the introduction of other routes of administration. The aim of this review is to make a reflection about still unclear and unidentified factors favoring severe reactions during SCIT. METHODS: Approaches to prevent fatal or life-threatening reactions to AIT and the current consensus on how to prevent life-threatening reactions to AIT have been taken into account. RESULTS: A decisive advance for SCIT safety was understanding that the major cause of mortality was injecting the allergen extract to patients with uncontrolled asthma. This awareness resulted in a significant decrease in fatalities, but not in their abolition, except for Hymenoptera venom immunotherapy. Among the factors favoring severe reactions there are the administration of a wrong extract or of allergen doses higher than listed, unintentional intravenous administration, and missed dose reduction after protracted interruption. Moreover, in the context of the improving of the safety, the role played in tolerance-promoting by adjuvants such as CpG oligodeoxynucleotides has to be taken into account, as well as the potential preventive effect performed by the monoclonal anti-IgE antibody omalizumab against the exacerbation of severe reactions during SCIT. CONCLUSIONS: The safety of SCIT is good, but the research to improve it further must continue. In particular, the pathophysiological mechanisms related to AIT for inhalants and for Hymenoptera venom should be studied, based on the evident diversity demonstrated by the complete absence of fatal reactions to Hymenoptera venom immunotherapy from its introduction in comparison with the history of serious and fatal offenses examined in this review. (www.actabiomedica.it) Mattioli 1885 2023 2023-08-03 /pmc/articles/PMC10440773/ /pubmed/37539607 http://dx.doi.org/10.23750/abm.v94i4.14239 Text en Copyright: © 2023 ACTA BIO MEDICA SOCIETY OF MEDICINE AND NATURAL SCIENCES OF PARMA https://creativecommons.org/licenses/by-nc-sa/4.0/This work is licensed under a Creative Commons Attribution 4.0 International License |
spellingShingle | Review Incorvaia, Cristoforo Cavaliere, Carlo Schroeder, Jan W. Leo, Gualtiero Nicoletta, Francesca Barone, Alessandro Ridolo, Erminia Safety and adverse reactions in subcutaneous allergen immunotherapy: a review |
title | Safety and adverse reactions in subcutaneous allergen immunotherapy: a review |
title_full | Safety and adverse reactions in subcutaneous allergen immunotherapy: a review |
title_fullStr | Safety and adverse reactions in subcutaneous allergen immunotherapy: a review |
title_full_unstemmed | Safety and adverse reactions in subcutaneous allergen immunotherapy: a review |
title_short | Safety and adverse reactions in subcutaneous allergen immunotherapy: a review |
title_sort | safety and adverse reactions in subcutaneous allergen immunotherapy: a review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10440773/ https://www.ncbi.nlm.nih.gov/pubmed/37539607 http://dx.doi.org/10.23750/abm.v94i4.14239 |
work_keys_str_mv | AT incorvaiacristoforo safetyandadversereactionsinsubcutaneousallergenimmunotherapyareview AT cavalierecarlo safetyandadversereactionsinsubcutaneousallergenimmunotherapyareview AT schroederjanw safetyandadversereactionsinsubcutaneousallergenimmunotherapyareview AT leogualtiero safetyandadversereactionsinsubcutaneousallergenimmunotherapyareview AT nicolettafrancesca safetyandadversereactionsinsubcutaneousallergenimmunotherapyareview AT baronealessandro safetyandadversereactionsinsubcutaneousallergenimmunotherapyareview AT ridoloerminia safetyandadversereactionsinsubcutaneousallergenimmunotherapyareview |